NCI Webinar: “Creating biobanking infrastructures that enable return of results”- March 29

The seminar series is brought to you by NCI’s Biorepositories and Biospecimen Research Branch (BBRB) and addresses current topics in biobanking science, policy and operations. In the era of precision medicine, high quality biospecimens are central to understanding complex diseases, biomarker discovery and unraveling the mechanisms of resistance to therapies. This seminar series is intended to be forward-looking with a focus on improving awareness of best practices for collection of biospecimens and associated data as well as expanding research participation through biobanking.

Our focus for spring 2022 is on “Creating biobanking infrastructures that enable return of results.” The seminar by Drs. Ramirez and Jewell, to be followed by a panel discussion with Dr. McCall, is the second of a two-part mini-series on this topic.

Tuesday 29th March 2022, 1:00 – 2:30 PM

Case Studies on Biobanking Infrastructures that Enable Return of Results

    Nilsa C. Ramirez, MD, FCAP
    Director, Biopathology Center (BPC) at Nationwide Children’s Hospital Professor, Clinical Pathology and member of Translational Therapeutics Program, OSU Comprehensive Cancer Center
  • Scott Jewell, Ph.D.,
    Director, Van Andel Research Institute (VARI) Core Technologies (8 cores) and VARI Pathology and Biorepository Core (PBC) Professor, Van Andel Institute Graduate School (VAIGS)
  • Shannon J. McCall, M.D.
    Assoc. Professor & Vice-chair for Translational Research, Dept. of Pathology Director, BioRepository & Precision Pathology Center Co-Leader, Precision Cancer Medicine & Innovative Therapeutics Program Duke Cancer Institute & Duke University School of Medicine

Participants must register using the WebEx link prior to the meeting

Case Study by Dr. Ramirez: Biobanking in the Context of Clinical Trials – The Biopathology Center Experience
Abstract: The Biopathology Center provides biobanking services to several NCI- sponsored clinical trial efforts (e.g., COG, SWOG, NRG Oncology, EET). For some of the clinical trials sponsored by these groups, it is necessary or required to support biospecimen processing in a CAP accredited/CLIA certified environment. Specimens processed under these regulatory requirements can be used for downstream clinical testing, patient stratification, and targeted treatments. This presentation will highlight our experience in this setting, including how our CAP BAP accredited research laboratory activities co-exist with our LAP accredited/CLIA certified clinical laboratory activities.

Case Study by Dr. Jewell: The Cancer Moonshot Biospecimen Core Resource
Abstract: A biospecimen core resource performs an array of tasks to meet the biospecimen management needs of a research project. When research projects are based on human biospecimens from research participants, clinically relevant findings may arise either as part of the intended project or incidentally. Like many biobanks that are involved in clinical trials, the advancement of research technologies continues to push the need for biobanks to teeter between the research and clinical utility of patient samples. The Van Andel Research Institute serves as the biospecimen core resource (BCR) for the Cancer Moonshot Biobank, which conducts clinical biomarker assays for enrolled research participants. This presentation will discuss the organization, description of services and the design of the BCR to develop and maintain the capability for clinical testing results to be returned to patients.

Please note that, with our speakers’ authorization, NCI records presentations for the NIH and the general public.
Event Contact Information: Veena Gopalakrishnan ( Individuals with disabilities who need reasonable accommodation to participate in this event should contact Veena Gopalakrishnan (, 240-276-5123, 3 days in advance of the seminar date to discuss accommodation needs.